Sanofi SA (SNY) FinancialsSNYFinancialSanofi SA

Sanofi SA (SNY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Others, accounting for 40.7% of total sales, equivalent to $9.33B. Other significant revenue streams include Dupixent and Polio / Pertrussis / Hib. Understanding this composition is critical for investors evaluating how SNY navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Sanofi SA maintains a gross margin of 69.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.79%, while the net margin is 8.37%. These profitability ratios, combined with a Return on Equity (ROE) of 5.72%, provide a clear picture of how effectively SNY converts its operational activities into shareholder value.

In the context of the broader market, SNY competes directly with industry leaders such as REGN and GSK. With a market capitalization of $104.76B, it holds a leading position in the sector. When comparing efficiency, SNY's gross margin of 69.24% stands against REGN's 86.56% and GSK's 75.42%. Such benchmarking helps identify whether Sanofi SA is trading at a premium or discount relative to its financial performance.

Sanofi reported second-quarter earnings of $1.22 per share on revenue of $13.48 billion, both exceeding analyst expectations, particularly with Dupixent sales climbing 38% to €5.15 billion.